OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
OmniAb, Inc. (OABI)
Company Research
Source: Business Wire
Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb™, the Company’s novel transgenic chicken platform launched in 2023 that generates fully human and stabilized sdAbs EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603162111/en/Image rendering of OmniAb’s OmnidAb™, a stabilized fully human heavy chain only single domain antibody (Graphic: Business Wire)sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks for antibody discovery.
Show less
Read more
Impact Snapshot
Event Time:
OABI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OABI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OABI alerts
High impacting OmniAb, Inc. news events
Weekly update
A roundup of the hottest topics
OABI
News
- OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology [Yahoo! Finance]Yahoo! Finance
- Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 34%? [Yahoo! Finance]Yahoo! Finance
- OmniAb to Participate in the Jefferies Global Healthcare ConferenceBusiness Wire
- OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston SummitBusiness Wire
- OmniAb, Inc. (NASDAQ: OABI) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.MarketBeat
OABI
Earnings
- 5/9/24 - Miss
OABI
Sec Filings
- 5/28/24 - Form 4
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- OABI's page on the SEC website